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Abstract
Background
Symptoms indicating acute coronary syndrome are commonly seen in emergency rooms,
but only 10% of patients are actually diagnosed with acute myocardial infarction (AMI). The
Guidelines for the diagnosis of patients with suspected AMI include either multiple testing of
cardiac troponin (cTN) or a single combined test of cTN and copeptin, which facilitates ear-
lier diagnosis or exclusion of AMI. The aim of the present analysis was to investigate the
impact of combined copeptin/cTN testing on health care resource consumption and related
costs both during and after initial hospital treatment.
Methods and results
The analysis was based on the BIC-8 trial and financial data of participating study sites. A
cost analysis was carried out primarily from the hospital perspective and secondarily from
the perspective of German statutory health insurers. The underlying assumptions of the
investigation were tested for robustness in additional sensitivity analyses. In total, the data
of 713 patients (n = 359 combined copeptin/cTN testing, n = 354 serial cTN testing) were
evaluated. From a hospital perspective, the combined copeptin/cTN testing showed a
reduced number of medical procedures and a lower frequency of inpatient admissions. The
average staff time was significantly reduced by a mean of 49 minutes (95% confidence inter-
val (CI) 46 to 53) per patient, accompanied by a significant mean reduction of 131 minutes
(95%CI 104 to 158) in the time patients stayed in the emergency room. The initial hospital
treatment was less cost-intensive. Over the entire study period, no significant cost differ-
ences were observed between the groups for health insurance.
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Conclusion
The combined copeptin/cTN testing has the potential to save costs and staff time in acute
care and for the entire hospital stay. The primary explanations for these findings are early
identification and ruling out patients without AMI along with the associated reduced need for
acute medical treatment.
Trial registration
ClinicalTrials.gov NCT01498731
Introduction
Signs and symptoms suggestive of acute coronary syndrome (ACS) are commonly found in
emergency departments (ED) and chest pain units (CPUs) but only 10% of these patients are
actually diagnosed with acute myocardial infarction (AMI) [1]. The current guidelines for the
management of patients with suspected non-ST-elevated myocardial infarction recommends
using either serial cardiac troponin (cTn) testing or the combined testing of copeptin and cTn
at admission to rule out AMI early [2]. The copeptin-based protocol has already been tested in
the prospective randomized clinical BIC-8 trial (Biomarkers In Cardiology-8) [3]. The primary
result of the BIC-8 trial showed the noninferiority of an early rule-out based on the proposed
copeptin algorithm compared to standard of care with serial cTn testing regarding patient
safety (30-day major adverse cardiac events (MACE)): copeptin 5.19% (95%CI 3.32 to 7.69),
vs. standard 5.17% (95%CI 3.30 to 7.65)). In this trial MACE was defined as all-cause death or
survived sudden cardiac death, AMI, rehospitalization for ACS, acute unplanned percutaneous
coronary intervention (PCI), coronary artery bypass grafting (CABG), and documented life-
threatening arrhythmias (ventricular tachycardia, ventricular fibrillation, complete atrioven-
tricular block, including events during the index hospital stay) [3]. Additionally, in the experi-
mental group, patient ED/CPU length of stay (LOS) was significantly reduced, and less
diagnostic measures were necessary.
Thus, the objective of the present analysis was to investigate how much the use of combined
copeptin/cTn testing affected resource consumption and related costs during the initial treat-
ment of participants of the BIC-8 trial in an acute care setting as well as after hospitalization.
Methods
The present health economic secondary analysis was based on BIC-8 trial data in combination
with data requested from the financial departments of the involved study sites. However, the
analysis was restricted to patients with hospital admission in only two university study sites in
Germany (Berlin, Heidelberg). This restriction was determined for due to two reasons. First,
comparisons of health economic results between different national health care systems are lim-
ited [4], so the analysis was restricted to patients from German study sites. In total, Berlin and
Heidelberg recruited 713 patients. These patients were 79% of all BIC-8 patients (n = 902), so
the restriction to these sites did not lead to substantial limitations regarding the included num-
ber of patients.
Study design
In the BIC-8 trial (ClinicalTrials.gov registration number NCT01498731), patients with sus-
pected ACS were included after they had contact to the ED in one of the participating study
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sites. Patients were randomized to either the copeptin group or the standard treatment group.
In the standard group, patients were managed according to the current European Society of
Cardiology (ESC) guidelines, including serial measuring of cTn. Copeptin values were also
measured in the standard group but not revealed to the treating staff to assure standard care.
In the copeptin group, cTn and copeptin were assessed, but in contrast to the standard group,
the copeptin value was used for further patient management. In cases of negative results for
both biomarkers, patients were considered to be low risk and could be early discharged into
outpatient care. Before discharge, patients had a final visit to ensure their well-being. The final
discharge decision was at the discretion of the attending physician who was allowed to overrule
the biomarker result. All discharged patients had an outpatient cardiology appointment within
a maximum of 3 days after discharge. In case of a positive copeptin result, patients were man-
aged equal to the standard group. Copeptin was measured from the routine blood sample at
admission using the Thermo Scientific BRAHMS Copeptin ultrasensitive KRYPTOR assay.
cTn was tested as by routine practice at the individual sites.
Possible pathways of the participating patients are shown in Fig 1. More details of the
underlying study design and inclusion/ exclusion criteria are reported elsewhere [3].
Types of economic analyses, analyzed time frame and costing perspectives
The economic analyses were focused on resource consumption and costs. This focus was
selected because the BIC-8 trial has shown comparability between the groups in terms of
Fig 1. Study overview (including patient pathways through the study, definition of analysis setting [1 –acute care setting, 2 –complete initial hospital setting, 3
–Total study duration] and costing perspectives [A–hospital perspective, B–Statutory health insurance perspective]).
https://doi.org/10.1371/journal.pone.0202133.g001
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MACE, which was the primary study outcome of this clinical trial [3]. This comparability was
also given in the analyzed subgroup of patients from German study sites, where the proportion
of MACE during the study was 5.01% (n = 18) in the copeptin group and 5.08% (n = 18) in the
standard group.
In the present analysis different time frames were analyzed (Fig 1). Because we were inter-
ested in obtaining a picture of the ED/CPU processes, the analysis was completed in three
steps: (1) the acute care setting, (2) the complete initial hospital setting, and (3) the 90 days fol-
low-up period. Additionally, the analysis was performed from two different perspectives. Pri-
mary costs were analyzed from the perspective of the participating study center (setting 1: ED/
CPU; setting 2: complete initial hospital stay). A secondary analysis was performed from the
perspective of German statutory health insurers (setting 1: ED/CPU, setting 2: complete initial
hospital stay; setting 3: 90-day follow-up).
Outcomes
According to the time frame of the study and the costing perspectives, study outcomes were
cost per patient in acute care setting of the ED/CPU (from both perspectives), cost per patient
for the complete initial hospital setting (from both perspectives), and costs for the total study
period (only statutory health insurance perspective). The predefined primary outcome was
mean cost per patient for the complete initial hospital setting from the hospital perspective.
Furthermore we analyzed the number of patients receiving procedures, invested staff per-
son-time and LOS in an acute care setting.
Resource consumption
During the initial stay in the acute care setting of the ED/CPU, resource consumption was doc-
umented by participating sites in electronic case report forms (eCRFs). These forms included
data the on number of blood samplings, electrocardiograms (ECG), echocardiography, medi-
cation, patient transfers and discharge. Additionally, to measure and report the person-time
for medical staff in ED/CPU, the mean time (in minutes for medical doctors and nursing staff)
needed for completing these single procedures were assumed based on expert hearing and
summarized on a patient level. For patients transferred to the ward afterwards, no further
information on concrete resource consumption in each ward was available.
After the initial hospital stay, patients had two follow-ups: 30 days and 90 days after ran-
domization. For this period, the number of PCIs and CABGs, further hospitalizations, and
clinical MACE was collected. These data were reported directly by the participating patients or
their close relatives. According to the study protocol, all patients allocated to the copeptin
group with early discharge from the ED/CPU should have had an outpatient cardiology
appointment. Therefore, one outpatient cardiologist contact was assumed during the follow-
up for each of these patients. For patients of the standard group who were directly discharged
from ED/CPU, one outpatient contact to cardiologists was assumed for 50% of them.
Cost assessment
The method for measuring the associated costs per patient depends on the costing perspective.
For the primary hospital perspective, the calculation of costs in the ED/CPU for all patients
was based on the number of documented procedures during the study multiplied by the stan-
dardized unit costs. For each procedure, common national unit costs published in the
DKG-NT handbook [5] (tariffs of the German hospital society) were used. The costs for medi-
cation were calculated based on the mean costs of daily defined dosages [6]. Because the
KRYPTOR assay was provided based on a reagent rental contract, costs for copeptin testing
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were assumed to be 16 Euro per test according to Domenico at al. 2013 [7]. For patients trans-
ferred to the ward after their initial visit in the ED/CPU, the costs from the hospital perspective
were provided by the financial departments of the participating centers. From the hospital per-
spective only the initial hospital stay was relevant, and resource consumption after and outside
of this initial stay (during follow-up) was not considered.
The costs arising in the ED/CPU from the health insurers’ perspective were only available for
patients without an inpatient stay. For these patients, we used the insurance outpatient reimburse-
ment rates received and provided by the financial departments of the hospitals. Because patients
transferred to the ward after initial ED/CPU visits are usually reimbursed by a DRG lump sum in
Germany, a differentiation was not possible between ED/CPU costs and costs that occurred on
the ward. However, for analyzing the complete hospital stay, these DRG costs were taken and
combined with outpatient reimbursement rates for patients discharged from the ED/CPU. In
contrast to the primary hospital perspective, resources and costs during the follow-up were cost-
relevant for statutory health insurers. Therefore standard unit costs, reflecting the statutory health
insurances perspective, were used to estimate the cost of outpatient cardiologist contacts [8–9],
hospitalizations for CABG or PCI, and further inpatient stays during the follow-up period.
All underlying unit costs used in the present analyses are provided in Table 1.
Statistical analysis
Data analysis was based on the intention to treat (ITT) approach. For analyzing the results for
the complete study period from a statutory health insurance perspective, only patients with
complete follow-up information were included. No missing values were replaced.
Baseline characteristics were presented as proportions (%) or mean values with standard
deviations (SD). The results of LOS and person-time invested by medical staff were tested by
using generalized linear models for significant differences. To consider the skewed nature of
cost data and potential differences between study arms, a generalized linear model with
gamma distribution and log link function was used for results of cumulated costs. Adjusted
results are shown as expected means and 95% confidence intervals (95%CIs) and mean group
differences including 95%CI. The results were adjusted for gender and age; individual risk fac-
tors including diabetes, hypertension, hyperlipidemia, family history of myocardial infarction,
smoking status; and medical history such as known coronary artery disease, prior myocardial
infarction, chronic heart failure, primary valve disease, cardiomyopathy, prior percutaneous
coronary intervention and prior coronary artery bypass graft. For the statistical model, default
settings of the statistical software were used. Thus the value for continuous covariates was set
to its overall mean estimate. In our model, the only continuous covariate was “age”, assuming
an equal mean age of 53.19 years for both groups. All other covariates used in the analysis had
dichotomous characteristics (yes/no) and were assumed with a share of 50% each in the
groups. Single cost data additionally were presented as raw means and 95% confidence inter-
vals as well as median values including interquartile range (75th and 25th percentiles).
The significance level was defined at 5% (two-sided). Because the primary outcome was
defined a priori, no adjustment for multiple testing was conducted [10]. Therefore, significant
results for secondary outcomes should be seen as hypothesis generating, not as definitive find-
ings. For all statistical analyses, SPSS version 23 was used. All results were double checked by a
second statistician using SAS 9.4.
Sensitivity analysis
In economic evaluations of health interventions, the sensitivities of a cost result to changes in
modeling assumptions, data variation, and sampling error are important. Any uncertainties in
Health economic analysis of copeptin/cardiac troponin testing
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our analysis would result essentially from two factors: the assumption of the calculation (stan-
dardized unit costs) and the heterogeneity of the patient sample. Therefore, uncertainty was
tested in additional sensitivity analyses for the primary outcome (mean cost per patient from
the hospital perspective for the complete initial hospital setting) in combination with person-
time invested by medical staff in ED/CPU. A probabilistic sensitivity analysis was used to
address the uncertainty resulting from assumptions on unit costs and time invested by staff.
Therefore, a Monte Carlo simulation process [11] was conducted that involved running the
analyses 1000 times using randomly sampled values for each of the standardized unit costs
shown in Table 1 and varying assumptions on person-time for medical staff simultaneously.
For varying cost inputs a gamma distribution, for data on person-time a normal distribution
was assumed. This simulation was based on the predefined input data range of ±50% maxi-
mum. Additionally, a bootstrap analysis with random 1000-fold resampling of the original
Table 1. Unit costs used for monetization of medical resource consumption.
Ressource Daily unit
cost
Source
Procedures in ED/CPU
Physical examination 6.87 Euro Based on Tariff of the German Hospital Society [5]
Electrocardiogram (ECG) 21.73 Euro
Blood sampling 7.58 Euro
Troponin testing 13.80 Euro
Echocardiography 60.13 Euro
Copeptin testing 16.00 Euro Domenico et al. 2013 [7]
Medication in ED/CPU
Nitro 0.28 Euro Drug Regulation Report 2014 [6]
ASS 0.07 Euro
Clopidogrel 0.52 Euro
Prasugrel 2.77 Euro
Ticagrelor 2.61 Euro
Fondaparinux 5.88 Euro
Unfractionated heparin 3.24 Euro
Low molecular weight
heparins
2.93 Euro
GIIbIIIainhibitors 0.86 Euro
Beta blockers i.v. 0.24 Euro
Beta blockers oral 0.24 Euro
Biuretics i.v. 0.16 Euro
Biuretics oral 0.16 Euro
Catecholamine’s 23.40 Euro
Antibiotics 1.66 Euro
Follow-up events
Outpatient cardiologist
visits
70.60 Euro Own calculation: based on Krauth et al.2005 [8] and Bock et al.2015 [9]
Hospitalization for PCI 3619.75 Euro Own calculation: Case Mix index cardiology 2012 (1.21) multiplied with
German DRG base rate in 2012 (2991.53 Euro)
Hospitalization for CABG 12609.29
Euro
Own calculation: CABG DRG F06F (cost weight 4.215) multiplied with
German DRG base rate in 2012 (2991.53 Euro)
Further hospitalization 2991.53 Euro DRG base rate in 2012 (2991.53 Euro)
values were varied within a range of ±50% maximum in sensitivity analysis
https://doi.org/10.1371/journal.pone.0202133.t001
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population was performed to determine to what extent the results may vary due to many repli-
cations of a trial. This analysis accounted for the heterogeneity around all health care resource
consumption observed in the study.
Both results of the Monte-Carlo simulations and the bootstrap samples were plotted into
the four-quadrant diagram, which gives graphical information on the results’ robustness. The
sensitivity analyses were performed by using MS Excel 2010.
Results
Baseline characteristics
Data of 713 patients (copeptin group, n = 359; standard group, n = 354) were available includ-
ing study documentation in electronic case report forms (eCRFs) and were complemented by
data provided by the financial departments of the participating study sites. Regarding patient
characteristics, both groups were well balanced in a number of the observed items (Table 2).
The mean age of the included patients was 53 years, and most patients were men. Both
groups had comparable distribution of cardiovascular risk factors such as increased body mass
index (BMI), hypertension or smoking status. Potential relevant differences were detectable
for hyperlipidemia, diabetes, family history of myocardial infarction and the proportion of ex-
smokers. Some differences were also observed regarding to the medical history of the patients,
especially for prior chronic heart failure and cardiomyopathy.
Table 2. Patients characteristics at baseline.
Copeptin (n = 359) Standard (n = 354)
Female patients (%) 40.4 35.6
Age (mean±SD) 52.9±16.2 53.3±15.4
Risk factors
BMI (mean±SD) 27.2±5.0 27.4±4.6
Diabetes (%) 11.7 13.0
Hypertension (%) 55.2 55.9
Hyperlipidaemia (%) 38.2 44.4
Family history of MI (%) 29.5 24.3
Smoker (%) 32.0 33.1
Ex-smoker (%) 34.0 31.1
GRACE-score (mean±SD) 80.1±26.2 79.7±26.3
TIMI risk score (mean±SD) 1.7±1.2 1.7±1.1
Medical history
Known CAD (%) 23.4 21.2
Prior MI(%) 10.9 12.4
CHF (%) 8.4 4.2
PVD (%) 7.5 8.2
Cardiomyopathy (%) 3.1 1.1
Prior PCI (%) 20.1 18.9
Prior CABG (%) 4.5 3.4
Abbreviations: SD–standard derivation; BMI–body mass index; MI–Myocardial infarction; CAD—coronary artery
disease; CHF–chronic heart failure; PVD—primary valve disease; PCI—percutaneous coronary intervention; CABG
—coronary artery bypass graft
https://doi.org/10.1371/journal.pone.0202133.t002
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LOS and staff person-time in acute care setting (ED/CPU)
Patients who received combined copeptin/cTn testing had a significant lower LOS in the ED/
CPU than those who received standard care (copeptin: adjusted mean LOS 244 minutes (95%
CI 181 to 307); standard: adjusted mean LOS 375 minutes (95%CI 309 to 440), adjusted mean
difference -131 minutes (95%CI -158 to -104); p<0.001). This result was primarily explained
by a lower number of patients receiving medical procedures (Table 3) and more patients dis-
charged earlier to outpatient care or transferred to the ward (Fig 2).
Particularly, the differences in the number of medical procedures had a direct effect on the
time resources spent by the medical staff for treating each patient. The total mean person-time
differed significantly (p<0.001) between the groups (Fig 3).
Table 3. Cost per patient from hospital perspective by timeframe.
Copeptin Standard
n affected mean
(95%CI)
median (IQR) n affected mean
(95%CI)
median (IQR)
(1) Acute care setting n = 359 n = 354
Phycical examination 359 6.87 Euro
(6.87 to 6.87)
6.87 Euro
(6.87; 6.87)
354 6.87 Euro
(6.87 to 6.87)
6.87 Euro
(6.87; 6.87)
1st ECG 359 21.73 Euro
(21.73 to 21.73)
21.73 Euro
(21.73; 21.73)
354 21.73 Euro
(21.73 to 21.73)
21.73 Euro
(21.73; 21.73)
2nd ECG 27 1.63 Euro
(1.04 to 2.23)
0.00 Euro
(0.00; 0.00)
173 10.62 Euro
(9.48 to 11.76)
0.00 Euro
(0.00; 21.73)
1st blood sampling 359 7.58 Euro
(7.58 to 7.58)
7.58 Euro
(7.58; 7.58)
354 7.58 Euro
(7.58 to 7.58)
7.58 Euro
(7.58; 7.58)
3 h blood sampling 44 0.93 Euro
(0.67 to 1.19)
0.00 Euro
(0.00; 0.00)
278 5.95 Euro
(5.63 to 6.28)
7.58 Euro
(7.58; 7.58)
6 h blood sampling 35 0.74 Euro
(0.51 to 0.97)
0.00 Euro
(0.00; 0.00)
202 4.33 Euro
(3.93 to 4.72)
7.58 Euro
(7.58; 7.58)
Troponin testing 359 16.83 Euro
(16.06 to 17.61)
13.80 Euro
(13.80; 13.80)
354 32.51 Euro
(31.65 to 33.06)
27.60 Euro
(27.60; 41.40)
Copeptin testing 359 16.00 Euro
(16.00 to 16.00)
16.00 Euro
(16.00; 16.00)
0 - -
Echocardiography 19 3.18 Euro
(1.78 to 4.58)
0.00 Euro
(0.00; 0.00)
84 14.27 Euro
(11.59 to 16.95)
0.00 Euro
(0.00; 0.00)
Medication 36 1.76 Euro
(0.53 to 2.98)
0.00 Euro
(0.00; 0.00)
200 4.60 Euro
(2.93 to 6.26)
0.62 Euro
(0.00; 3.49)
Sum acute care setting 359 77.26 Euro
(73.92 to 80.60)
65.98 Euro
(65.98; 65.98)
354 108.46 Euro
(104.69 to 112.22)
114.47 Euro
(73.31; 118.47)
Sum acute care setting
adjusted mean
p<0.001 359 81.17 Euro (72.46 to 90.92) 354 114.61 Euro (101.98 to 128.79)
(2) Complete hospital stay n = 359 n = 354
Sum acute care setting 359 76.99 Euro
(73.76 to 80.22)
65.98 Euro
(65.98; 65.98)
354 108.38 Euro
(104.66 to 112.10)
114.47 Euro
(73.31; 118.47)
Ward 97 683.79 Euro
(324.37 to 1043.21)
0.00 Euro
(0.00; 291.78)
219 582.71 Euro
(452.24 to 713.18)
347.10 Euro
(0.00; 492.03)
Sum complete hospital stay 359 761.05 Euro
(400.91 to 1121.19)
65.98 Euro
(65.98; 373.45)
354 691.16 Euro
(558.46 to 823.87)
453.53 Euro
(93.00; 606.24)
Sum complete hospital stay (primary outcome)
adjusted mean
p = 0.025 359 473.50 Euro (280.64 to 798.89) 354 633.97 Euro (377.57 to 1064.47)
 adjusted for gender and age; individual risk factors: diabetes, hypertension, hyperlipidaemia, family history of myocardial infarction, smoking status; medical history:
known coronary artery disease, prior myocardial infarction, chronic heart failure, primary valve disease, cardiomyopathy, prior percutaneous coronary intervention,
prior coronary artery bypass graft
https://doi.org/10.1371/journal.pone.0202133.t003
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The adjusted total mean invested staff person-time for the copeptin group was approxi-
mately 154 minutes (95%CI 146 to 163) and 204 minutes (95%CI 195 to 212) for standard
Fig 2. Patients’ length of stay (LOS) in the acute care setting of emergency department/Chest pain unit (ED/
CPU).
https://doi.org/10.1371/journal.pone.0202133.g002
Fig 3. Adjusted mean person-time medical staff per patient in the acute care setting of emergency department/
Chest pain unit (ED/CPU).
https://doi.org/10.1371/journal.pone.0202133.g003
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group, resulting in significant (p<0.001) mean difference of approximately -49 minutes (95%
CI -53 to -46). Significant group differences were also detectable regarding the time invested
for treatment by the type of professional groups. The mean staff time saved in the copeptin
group was 31 minutes (95%CI 29 to 33, p<0.001) per patient for nursing staff and about 19
minutes (95%Ci 16 to 21, p<0.001) per patient for physicians.
Costs per patient from primary hospital perspective
Due to the lower number of medical procedures, the copeptin group had significantly
(p<0.001) lower total costs in the acute care setting of the ED/CPU from a hospital perspective
(Table 3). The adjusted mean cost per patient was 81.17 Euro (95%CI 72.46 to 90.92) in the
copeptin group and 114.61 Euro (95%CI 101.98 to 128.79) in the standard group (adjusted
mean difference -33.42 Euro (95%CI -39.52 to -27.35)). These group differences can be
explained in particular by a lower number of patients who received further blood samplings
after 3 and 6 h, had echocardiograms, and took medications in the copeptin group (Table 3).
These results are also confirmed with respect to the total costs during the entire hospital
stay (including the costs for inpatients with inpatient billing), which are defined as the primary
outcome of this analysis. Thus, the mean total cost per patient was significantly lower for the
copeptin group (copeptin: adjusted mean 473.50 Euro (95%CI 280.64 to 798.89); standard:
adjusted mean 633.97 Euro (377.57 to 1064.47); adjusted mean difference -160.47 Euro (95%
CI -301.21 to -19.73); p = 0.025).
Costs per patient from secondary statutory health insurers’ perspective
From a statutory health insurers’ perspective (Table 4), patients in the copeptin group seem to
be slightly more expensive during their stay in the acute care setting (copeptin: adjusted mean
82.70 Euro (95%CI 67.30 to 101.62); standard: adjusted mean 72.55 Euro (95%CI 58.20 to
90.43); adjusted mean difference 10.15 Euro (95%CI 3.48 to 16.82); p = 0.003).
However, the informative value of this result is limited because it was restricted to patients
with outpatient billing and did not include all patients who were reimbursed for inpatient
treatment by a DRG. For this reason, the costs of the entire hospital stay including all patients
are more meaningful, and the principal findings from the hospital perspective are essentially
confirmed here. Thus, for health insurers, the complete hospital stay of the copeptin group was
associated with adjusted mean costs per patient of 655.06 Euro (95%CI 388.78 to 1103.67)
compared to 805.40 Euro (95%CI 481.80 to 1346.34) in the standard group (adjusted mean dif-
ference -150.34 Euro (95%CI -317.61 to 16.93 to); p = 0.078), primarily explained by the group
differences in inpatient billing.
During the follow-up period, these savings were partly compensated for by higher mean
costs in the copeptin group. Because patients with early rule-out should have had an outpatient
cardiologist’s visit, additional costs associated with this physician contact occurred in the
copeptin group. Additionally, during the study follow-up hospitalization costs were higher in
the copeptin group. Finally, the adjusted total mean costs during the complete study duration
were not significantly higher for the copeptin group (copeptin: adjusted mean 1610.08 Euro
(95%CI 918.32 to 2822.91); standard: adjusted mean 1301.02 Euro (95%CI 744.46 to 2273.69);
adjusted mean difference 309.05 Euro (95%CI -51.72 to 669.83); p = 0.093).
Sensitivity analysis
The simultaneous random sampling of unit cost assumptions and assumptions on person-
time for medical staff, which was realized in the Monte Carlo analysis within a range of ±50%,
essentially confirms the robustness of the primary outcome result. Both cost differences
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between the groups and person-time for medical staff were comparably stable with benefits for
the copeptin group. The same applied to the results of the bootstrap analysis, which accounted
for potential uncertainty around all health care resource consumption and potential outliers
observed in the study participants. Fig 4 shows a scatter plot of all replicated results for both
types of sensitivity analyses.
Most single dots are located in the lower left-hand quadrant, indicating a probability of
81% for lower costs and staff time savings for patients with copeptin testing. This means that
the primary outcome is sufficiently confirmed even after considering alternative assumptions
or patient distributions.
Discussion
From an economic point of view, our analysis demonstrated the usefulness of copeptin testing
as an additional marker for the early rule-out of patients with suspected ACS in emergency
Table 4. Cost per patient from statutory health insurers’ perspective by timeframe.
Copeptin Standard
n affected mean
(95%CI)
median (IQR) n affected mean
(95%CI)
median (IQR)
(1) Acute care setting# n = 262 n = 135
Sum acute care setting 262 89.69 Euro
(82.82 to 96.55)
77.10 Euro (66.15; 79.90) 135 77.47 Euro
(68.13 to 86.82)
66.02 Euro
(66.02; 66.02)
Sum acute care setting
adjusted mean
p = 0.003 262 82.70 Euro (67.30 to 101.62) 135 72.55 Euro (58.20 to 90.43)
(2) Complete hospital stay n = 359 n = 354
Sum complete hospital stay 359 857.29 Euro
(484.02 to 1230.56)
77.10 Euro (76.46; 589.02) 354 758.20 Euro
(617.70 to 898.70)
611.19 Euro (66.02; 654.08)
Sum complete hospital
stay
adjusted mean
p = 0.078 359 655.06 Euro (388.79 to 1103.67) 354 805.40 Euro (481.80 to 1346.34)
(3) Total study duration† n = 321 n = 312
Sum complete hospital stay 321 908.73 Euro
(492.56 to 1324.90)
77.10 Euro (76.46; 600.10) 312 730.96 Euro
(581.94 to 879.97)
610.98 Euro (66.02; 654.08)
Outpatient cardiologist follow-up 234 51.47 Euro
(48.01 to 54.92)
70.60 Euro (0.00; 70.60) 62 13.91 Euro
(11.99 to 15.84)
0.00 Euro
(0.00; 35.30)
Further hospitalization follow-up 29 354.14 Euro
(214.89 to 493.39)
0.00 Euro
(0.00; 0.00)
21 287.65 Euro
(160.72 to 414.57)
0.00 Euro
(0.00; 0.00)
Hospitalization for PCI follow-up 38 496.17 Euro
(339.09 to 653.24)
0.00 Euro
(0.00; 0.00))
26 324.85 Euro
(200.69 to 449.01)
0.00 Euro
(0.00; 0.00)
Hospitalization for CABG follow-up 3 117.84 Euro
(0.00 to 251.28)
0.00 Euro
(0.00; 0.00)
2 80.82 Euro
(0.00 to 193.10)
0.00 Euro
(0.00; 0.00)
Sum follow-up 321 1019.61 Euro
(762.68 to 1276.54)
70.60 Euro
(70.60; 70.60)
312 707.24 Euro
(474.30 to 940.18)
0.00 Euro
(0.00; 35.30)
Sum total study duration 321 1928.34 Euro
(1352.97 to
2503.72)
156.21 Euro
(147.70;2578.85)
312 1438.20 Euro
(1156.35 to
1720.04)
620.98 Euro
(101.32;684.30)
Sum total study duration
adjusted mean
p = 0.093 321 1610.08 Euro (918.32 to 2822.91) 312 1301.02 Euro (744.46 to 2273.69)
# only available for patients with outpatient billing
† only available for patients with complete follow up
 adjusted for gender and age; individual risk factors: diabetes, hypertension, hyperlipidaemia, family history of myocardial infarction, smoking status; medical history:
known coronary artery disease, prior myocardial infarction, chronic heart failure, primary valve disease, cardiomyopathy, prior percutaneous coronary intervention,
prior coronary artery bypass graft
https://doi.org/10.1371/journal.pone.0202133.t004
Health economic analysis of copeptin/cardiac troponin testing
PLOS ONE | https://doi.org/10.1371/journal.pone.0202133 August 23, 2018 11 / 15
departments. From the hospital perspective, this testing saves person staff time and reduces
LOS in the ED/CPU. Therefore, the use of this testing may be a helpful strategy to handle over-
crowding in the acute care setting and to save hospital resources for the treatment of other
severely ill patients. Additionally, the use of copeptin testing saves costs in treatment, especially
by an early identification of patients without myocardial infarction requiring less medical
acute care procedures. More efficient running hospitals can be seen as an added value to a
health care system. From a statutory health insurers’ perspective, the combined copeptin/cTn
testing was related to lower costs for initial hospital admission primarily due to a reduced
number of patients in need of inpatient medical care. During the complete study period both
groups were not significantly different in term of costs.
To our knowledge this is the first economic evaluation of copeptin for early rule-out of ACS
in an emergency department or CPU setting in Germany. Our principal findings are in line
with the results of a previous study from Italy that demonstrated the association of copeptin
testing with cost savings and less procedural efforts [7]. Our findings are also confirmed by
other studies that compared the economic consequences of accelerated rule-out protocols in
ACS patients with repeated measurements. Ambavane et al. 2017 compared a 1h rule-out algo-
rithm based on high sensitivity troponin T (hsTnT) with standard of care treatment in a non-
randomized, multicenter design [12]. Thus, in this study, all patients were diagnosed with
repeated measurements, and cost-savings and reduction of LOS and staff time were only
assumption-based findings. The investigators estimated an ED-LOS of 4.3h for early rule-out
treatment and 6.5h for the standard treatment. These estimations were confirmed in our study
with a randomized approach. Additionally, the total in-hospital costs were found to be
Fig 4. Sensitivity analyses of the primary outcome (adjusted mean cost per patient from hospital perspective for
the complete initial hospital setting) in combination with person-time for medical staff in the acute care setting of
emergency department/Chest pain unit (ED/CPU).
https://doi.org/10.1371/journal.pone.0202133.g004
Health economic analysis of copeptin/cardiac troponin testing
PLOS ONE | https://doi.org/10.1371/journal.pone.0202133 August 23, 2018 12 / 15
significantly lower for early rule-out treatment than for standard of care treatment. Another
study by Cheng et al. 2016 investigated an accelerated hsTnT diagnostic protocol (Brisbane
protocol) in a tertiary care hospital in Australia using a pre-post comparison [13]. This study
also showed a reduction in expected LOS and costs. Even though their standard group had a
shorter LOS in the ED (median 5.6h) than our standard group, the reduction in ED LOS was
lower when the Brisbane protocol was applied (median 4.7h). The Brisbane protocol includes
a second hsTn testing 2h after admission, which may explain this lower reduction in ED LOS.
In line with the findings of our study, overall in-hospital costs were lower when the accelerated
rule-out was applied; however, ED costs were higher for the Brisbane protocol group than the
standard treatment group (standard AUD 882; Brisbane protocol AUD 976). The study group
from Brisbane also published a cost prediction model and an economic microsimulation
applied in an observational cohort [14]. In this simulation, five different hsTn-based algo-
rithms were compared, and the results again showed that early rule-out algorithms reduce hos-
pital costs and LOS in the ED. These effects were primarily seen for non-ACS patients; there
were no differences regarding these outcome variables in ACS patients. In a randomized
approach, Kaambwa et al. 2017 further compared conventional cardiac troponin testing to
hsTn and demonstrated that hsTnT leads to fewer adverse events but also higher costs during
a 12-month follow-up period [15]. The authors concluded that substantial changes in clinical
practice are required in order to reach cost-effectiveness of hsTnT as a routine procedure.
Although the studies are less comparable, this finding was in contrast to our analysis. Even
though the BIC-8 trial had a shorter follow-up period we found no significant differences
regarding health care costs between the groups when mean values were analyzed over the com-
plete study duration. Additionally, Vaidya et al. 2014 compared hsTnT to conventional tropo-
nin testing based on a decision analytical model. They concluded that hsTnT is a cost effective
diagnostic alternative to conventional cTnT [16]. Another study comparing diagnostic proto-
cols was published by Shortt et al. in 2017 [17]. They investigated the cost-effectiveness of diag-
nostic protocols based on troponin in combination with glycemic biomarkers (glucose,
HbA1c) compared to the guideline recommended 0h algorithm using an observational study
design. The authors concluded that the application of hsTnT in combination with glucose at
presentation is more safe and cost-effective than the 0h hsTnT rule-out algorithm.
The present analysis was particularly characterized by its randomized design and compara-
tively high number of participants. Most of the other economic evaluations mentioned above,
however, did not apply randomized designs. Furthermore, in the present analysis, it was possi-
ble to combine different data sources in the analysis, including real cost information provided
by the participating hospitals. Nevertheless, the analysis contains potential limitations that
readers should take into account when interpreting the results. First, the results were based on
a number of different assumptions, such as the person minutes spent for medical procedures
in acute care and the unit costs used for monetization of resources. To evaluate associated
uncertainties, we conducted sensitivity analyses allowing varying underlying assumptions
within realistic ranges, and these analyses confirmed our major findings. Second, this study
had some statistical outliers, and as a common difficulty when analyzing cost data, we had to
decide how to handle them. In our analysis five patients (copeptin n = 4, standard n = 1) had
costs of more than 10000 Euro during their inpatient stay. In addition to their cardiac com-
plaints, these patients had other accompanying severe diagnoses (e.g. ICD B90.9 sequelae of
respiratory and unspecified tuberculosis, ICD N.17 acute renal failure, ICD J44 chronic
obstructive pulmonary disease), which probably explained their high costs. Nevertheless, in
our analyses, we decided to involve all patients in order to reflect real world and to avoid sub-
jective inclusion/exclusion decisions. Third, our analysis used study sites that were located in
an urban university setting, which restricts the generalization of the results (e.g. for smaller
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hospitals in rural areas). Nevertheless, BIC-8 was a multicenter study, and two study centers
were considered in this analysis. Compared to other cost-effectiveness studies that were pri-
marily based on single-center data or assumption-based model calculations, the use of real
BIC-8 data in our analyses was an improvement. However, the transferability of our findings
(especially for cost results) to other national health care systems is limited, as national health
systems differ structurally in many aspects by country [4]. Fourth, the present economic evalu-
ation was performed in a retrospective setting, because the underlying BIC-8 trial was initially
designed as a clinical study and did not consider planning for health economic questions. For
this reason, not all possible cost-relevant outcomes were taken into account, especially in the
follow-up of the analysis. Fifth, the follow-up period of our analysis was not longer than 90
days, which may be too short to reflect all relevant long-term consequences. A comprehensive
health economic analysis would require the consideration of all relevant resources and costs
(e.g. medication after discharge) over a sufficiently long-time period, a condition that could
not be fulfilled using the retrospective study setting. Further studies investigating the use of
biomarkers should include possible health economic analyses during the study planning
phase.
Conclusion
This is the first extensive evaluation of cost and resource consumption associated with the
application of a single combined copeptin/cTn early rule-out protocol in patients with sus-
pected ACS in the ED in Germany. Based on our findings, a management process integrating
early rule-out testing with combined copeptin/cTn in these patients is not only as safe as serial
cTn testing but also bears the potential to save staff time and costs accumulated in the acute
care setting and the entire hospital stay.
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